drugset
drugset / Trial / NCT03239340

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

NCT03239340 ↗

Phase 2 Completed 154 enrolled AstraZeneca Parexel · collab
NaSingle-groupOpen-labelTreatment

Summary

A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib.

Timeline

Start
2018-05-30
Primary completion
2023-09-19
Completion
2023-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Osimertinib Small molecule 40 mg Oral
Subject Osimertinib Small molecule 80 mg Oral

Indications

lung cancer